3 news items
Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma
TPST
18 Jun 24
is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
TPST
7 Jun 24
Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
TPST
9 May 24
Therapeutics Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small
- Prev
- 1
- Next